期刊
ACS MEDICINAL CHEMISTRY LETTERS
卷 1, 期 2, 页码 64-69出版社
AMER CHEMICAL SOC
DOI: 10.1021/ml9000276
关键词
Hepatitis C virus NS3 serine protease inhibitor; alpha-ketoamide; narlaprevir; SCH 900518
Boceprevir (SCH 503034), 1, a novel HCV NS3 serine protease inhibitor discovered in our laboratories, is currently undergoing phase III clinical trials. Detailed investigations toward a second generation protease inhibitor culminated in the discovery of narlaprevir (SCH 900518), 37, with improved potency (similar to 10-fold over 1), pharmacokinetic profile and physicochemical characteristics, currently in phase II human trials. Exploration of synthetic sequence for preparation of 37 resulted in a route that required no silica gel purification for the entire synthesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据